Nordic Life Science
Advertising
Nordic Life Science
The latest business news
The company extends the project portfolio to projects in autoimmune diseases. Idogen´s technology is designed for the development of tolerogenic cell therapy in a variety of areas, especially treatment of
The company’s antibiotic-eluting product CERAMENT G has been approved by Health Canada. CERAMENT G is a CE-marked gentamicin-eluting injectable ceramic bone graft substitute on the market. CERAMENT G sales have
Swedish medtech company Coala Life has been named Cool Vendor by Gartner. The nomination is made for the market for Health and Wellness Device and Coala receives the award together
The Swedish national government gives clearance to the detailed plan for Science Village at the European Spallation Source (ESS) in Brunnshög, Lund. The Swedish Radiation Safety Authority’s study has given answers
LEO Pharma has entered into a definitive agreement to buy Bayer’s global prescription dermatology unit, including branded topical prescription treatments for acne, fungal skin infections and rosacea, and a range
In a new collaborative study with a major global pharma company, Immunovia’s blood-based testing platform, IMMray could differentiate healthy controls from non-small cell lung cancer (NSCLC) samples with a 95 % accuracy,
Advertising
Drug & Device development
The Swedish company has announced the results of a preclinical study confirming the potential for its NanoZolid technology for use with STING agonists, a novel cancer immunotherapy treatment. Due to
The company announces the status of the ongoing phase I/IIa clinical trial CANFOUR investigating the lead compound CAN04 (nidanilimab) and further information on the phase IIa part of the trial.
The company announces results from its extension study of its Phase 2 study investigating the safety and immune responses of its universal RSV vaccine, MVA-BN RSV, in an older adult
The company begins clinical development of yet another potential new treatment of Parkinson’s disease with the enrollment of the first participant in a phase I study with the compound Lu
The first patient has been dosed in a Phase 2 study evaluating the combination therapy of its cancer vaccine, CV301, and Bristol Myers Squibb’s checkpoint inhibitor, nivolumab (OPDIVO), for the
The company has reported positive results from a preclinical study in the field of acute kidney injury (AKI). The primary endpoints show that the active substance in the company’s candidate
Trelleborg Supports Engineers Developing Drug-eluting Devices 7 August 2018 by Trelleborg Life Science
Shorten your study start-up time with PCG Clinical Services & Viedoc! 11 July 2018 by PCG Clinical Services
New development in the field of Liquid Handling: Highly viscous substances such as collagen are now pipettable 28 June 2018 by Eppendorf Nordic
The company extends the project portfolio to projects in autoimmune diseases. Idogen´s technology is designed for the development of tolerogenic cell therapy in a variety of areas, especially treatment of
Advertising
Latest news
The Swedish company has announced the results of a preclinical study confirming the potential for its NanoZolid technology for use with STING agonists, a novel cancer immunotherapy treatment. Due to
Trelleborg Supports Engineers Developing Drug-eluting Devices 7 August 2018 by Trelleborg Life Science
Shorten your study start-up time with PCG Clinical Services & Viedoc! 11 July 2018 by PCG Clinical Services
New development in the field of Liquid Handling: Highly viscous substances such as collagen are now pipettable 28 June 2018 by Eppendorf Nordic
Our region is filled with life science activity. We take a closer look at what´s going in our Nordic cities when it comes to life science efforts, progress and challenges.
In focus – Nordic cities
Nordic Life Science
The latest clinical trials
The Swedish company has announced the results of a preclinical study confirming the potential for its NanoZolid technology for use with STING agonists, a novel cancer immunotherapy treatment. Due to
The company announces the status of the ongoing phase I/IIa clinical trial CANFOUR investigating the lead compound CAN04 (nidanilimab) and further information on the phase IIa part of the trial.
The company announces results from its extension study of its Phase 2 study investigating the safety and immune responses of its universal RSV vaccine, MVA-BN RSV, in an older adult
The company begins clinical development of yet another potential new treatment of Parkinson’s disease with the enrollment of the first participant in a phase I study with the compound Lu
The first patient has been dosed in a Phase 2 study evaluating the combination therapy of its cancer vaccine, CV301, and Bristol Myers Squibb’s checkpoint inhibitor, nivolumab (OPDIVO), for the
The company has reported positive results from a preclinical study in the field of acute kidney injury (AKI). The primary endpoints show that the active substance in the company’s candidate
Oncopeptides present updated interim data from the ongoing HORIZON trial with Ygalo at the 23rd Congress of The European Hematology Association (EHA). The updated phase II-data show a clinical data
AstraZeneca and Eli Lilly and Company are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibitor, for the treatment of Alzheimer’s disease.
Follicum announces that all patients in the Phase IIa clinical trial with FOL-005 for stimulating hair growth have been recruited. The trial is conducted at the Clinical Research Center for
The latest research news from the Nordic region
Science Article
The Swedish national government gives clearance to the detailed plan for Science Village at the European Spallation Source (ESS) in Brunnshög, Lund. The Swedish Radiation Safety Authority’s study has given answers
Just before summer, the last piece of the puzzle in the building of the new Campus Flemingsberg, was inauguarated, forming a new hub of biomedical research in the Stockholm region.
Researchers from the University of Copenhagen have discovered a hitherto unknown error in the transport of glutamine between astrocytes and neurons in the brains of mice with Huntington’s disease. In a
Scientists at Karolinska Institutet have discovered that one of the building blocks in the calcium channels in the pancreatic beta cells play an important role in regulating our blood glucose
He gets the prize for developing novel microscopy techniques and methods to improve the ability to obtain information from biological specimens. Thomas Deerinck is a research scientist, technical specialist and
The President of Karolinska Institutet has made the decision to find seven researchers responsible for scientific misconduct in the Macchiarini case. The case concerns six articles published in the scientific